Literature DB >> 2974097

Use of vasopressin antagonists in human diseases.

M Thibonnier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2974097

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN： 0098-6577            Impact factor:   10.545


× No keyword cloud information.
  5 in total

1.  Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin.

Authors:  F A László; C Varga; T Dóczi
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

Review 2.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

3.  Evidence for intact V1-vasopressin receptors in congenital nephrogenic diabetes insipidus.

Authors:  N Knoers; P M Janssens; J Goertz; L A Monnens
Journal:  Eur J Pediatr       Date:  1992-05       Impact factor: 3.183

4.  Activation of Vasopressin System During COVID-19 is Associated With Adverse Clinical Outcomes: An Observational Study.

Authors:  Claudia Gregoriano; Alexandra Molitor; Ellen Haag; Alexander Kutz; Daniel Koch; Sebastian Haubitz; Anna Conen; Luca Bernasconi; Angelika Hammerer-Lercher; Christoph A Fux; Beat Mueller; Philipp Schuetz
Journal:  J Endocr Soc       Date:  2021-03-17

5.  Risk assessment of sepsis through measurement of proAVP (copeptin): a secondary analysis of the TRIAGE study.

Authors:  Milena Kloter; Claudia Gregoriano; Ellen Haag; Alexander Kutz; Beat Mueller; Philipp Schuetz
Journal:  Endocr Connect       Date:  2021-08-24       Impact factor: 3.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.